A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab.

Autor: Edson ‐ Heredia, E., Banerjee, S., Zhu, B., Maeda ‐ Chubachi, T., Cameron, G.S., Shen, W., Heffernan, M.P., Gordon, K.B., Leonardi, C.L.
Předmět:
Zdroj: Journal of the European Academy of Dermatology & Venereology; May2016, Vol. 30 Issue 5, p864-865, 2p
Abstrakt: The article focuses on a study which examined the efficacy of ixekizumab in treating patients with psoriasis vulgaris. Clinical information on psoriasis vulgaris is provided, along with a description of the medical history of the study subjects. Study authors found increased improvement in patients who received ixekizumab in terms of health-related quality of life and pruritus symptom relief.
Databáze: Complementary Index